Present and future evolution of advanced breast cancer therapy.
Present and future evolution of advanced breast cancer therapy.
复制标题
DOI：
10.1186/bcr2572
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Alvarez RH
中科院分区：
文献类型：
--
作者：
Alvarez RH
虽然新疗法和药物组合的引入改善了转移性乳腺癌的预后，但这种疾病仍然无法治愈。对乳腺癌生物学和分子改变的了解的增加促进了靶向治疗的设计。这些药物包括受体和非受体酪氨酸激酶抑制剂（表皮生长因子受体家族）、细胞内信号传导途径（磷脂酰肌醇-3-激酶、AKT、雷帕霉素的哺乳动物靶标）血管生成抑制剂和干扰DNA修复的药物（聚（ADP-核糖）聚合酶抑制剂）。在本综述中，我们介绍了这些新的靶向治疗和新的靶向治疗与细胞毒性药物的组合的最有前途的研究。
Although the introduction of novel therapies and drug combinations has improved the prognosis of metastatic breast cancer, the disease remains incurable. Increased knowledge of the biology and the molecular alterations in breast cancer has facilitated the design of targeted therapies. These agents include receptor and nonreceptor tyrosine kinase inhibitors (epidermal growth factor receptor family), intracellular signaling pathways (phosphatidylinositol-3-kinase, AKT, mammalian target of rapamycin) angiogenesis inhibitors and agents that interfere with DNA repair (poly(ADP-ribose) polymerase inhibitors). In the present review, we present the most promising studies of these new targeted therapies and novel combinations of targeted therapies with cytotoxic agents.